These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30541682)

  • 1. Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus.
    García Díaz E; Ramírez Medina D; Morera Porras ÓM; Cabrera Mateos JL
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):223-231. PubMed ID: 30541682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
    Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
    Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III.
    Alanezi M; Yan AT; Tan MK; Bourgeois R; Malek-Marzban P; Beharry R; Alkurtass S; Gyenes GT; Nadeau PL; Nwadiaro N; Jedrzkiewicz S; Gao D; Chandna H; Nelson WB; Goodman SG;
    Cardiology; 2024; 149(3):266-274. PubMed ID: 38290490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inertia and treatment compliance in patients with type 2 diabetes in primary care].
    López-Simarro F; Brotons C; Moral I; Cols-Sagarra C; Selva A; Aguado-Jodar A; Miravet-Jiménez S
    Med Clin (Barc); 2012 Apr; 138(9):377-84. PubMed ID: 22036458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypolipidemic and antihypertensive therapy in diabetic patients in the Czech Republic: notes on the VZP (General Health Insurance Company) Data].
    Šnejdrlová M; Češka R; Janíčková-Žďárská D; Honěk P; Dušek P; Pavlík T; Kvapil M
    Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S30-7. PubMed ID: 26652963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Main barriers in the management of dyslipidaemias: Intolerants.
    Mostaza JM; Lahoz C
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():40-45. PubMed ID: 33966812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study).
    Bayram F; Sonmez A; Haymana C; Sabuncu T; Dizdar OS; Gurkan E; Carlioglu AK; Agbaht K; Ozdemir D; Demirci I; Barcin C; Salman S; Tetiker T; Balci MK; Kebapci N; Ersoy C; Yumuk V; Toth PP; Satman I;
    Lipids Health Dis; 2020 Nov; 19(1):237. PubMed ID: 33176832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
    De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new approach to the treatment of dyslipidemia].
    Kevelaitiene S; Slapikas R
    Medicina (Kaunas); 2008; 44(5):407-13. PubMed ID: 18541958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering drug prescriptions in a group of Colombian patients.
    Gaviria-Mendoza A; Machado-Duque ME; Machado-Alba JE
    Biomedica; 2019 Dec; 39(4):759-768. PubMed ID: 31860186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.
    Kondo Y; Hamai J; Nezu U; Shigematsu E; Kamiko K; Yamazaki S; Yoshii T; Takahashi M; Takano T; Kawasaki S; Yamada M; Yamakawa T; Terauchi Y
    Endocr J; 2014; 61(4):343-51. PubMed ID: 24452015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
    Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes.
    Karalis DG
    Clin Cardiol; 2008 Jun; 31(6):241-8. PubMed ID: 17847038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
    Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
    Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
    Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New indications and therapeutic objectives for dyslipidemia].
    Maiques Galán A
    Aten Primaria; 2006 Nov; 38(9):473-5. PubMed ID: 17194348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.